Purpose Adjuvant radiotherapy is the standard postoperative treatment after conservative surgery in high risk soft tissue sarcoma. The role of adjuvant chemotherapy is still debated. Therefore, a matched cohort analysis was performed in high risk soft tissue patients to analyse differences in terms of clinical outcome and toxicity between patients treated with concomitant radio-chemotherapy (RTCT) and radiotherapy (RT) alone. Materials and Methods For each patient in RT group was selected a patient in the RTCT group matching for age, T stage and grading. Acute and late toxicity were recorded, overall survival, recurrence free survival and distant metastases free survival were analysed and compared between the two groups. Results Ninety patients were selected, half of patients underwent radio-chemotherapy and half received radiotherapy alone. During the treatment Grade 3 dermatitis was recorded in 15 (16.7%) patients, 6 (6.7%) patients associated chemotherapy and during follow up 12 (13.3%) patients developed grade 2 late fibrosis, 3 (3.3%) joint stiffness and 1 (1.1%) patient experienced a bone fracture. There were no differences in the rate of acute and late toxicity between RTCT and RT alone group. Nineteen (21.1%) patients developed local recurrence, overall 5-year local relapse free survival was 83%. There were no differences between the two groups. 29 patients developed distant metastases, 14 (15.6%) patients in the RTCT group and 15 (16.7%) patients in the RT group. The 5-year distant metastases free survival was 67%. Age > 65 years was the only independent factor affecting distant recurrence (HR = 5.7, 95% CI 2.7-11.9; p = 0.001). At the time of analysis 15 (16.7%) patients were dead, 6 (6.7%) patients in the RTCT group and 9 (10%) patients in the RT group. 5-years overall survival was: 88%. At multivariate analysis age > 65 years was an independent prognostic factor of overall survival (HR = 3.7, 95% CI 1.2-12.1, p = 0.037). Conclusions Prospective randomized studies with large size population and with subgroup analysis for histological subtypes are necessary to clarify the role of adjuvant chemotherapy in soft tissue sarcoma patients. Tailored treatment has to be considered in elderly soft tissue patients to guarantee a better outcome in this high risk and fragile population.
Introduction
Soft tissue sarcomas (STSs) are a rare disease accounting less than 1% of all adult neoplasms [1] . STSs derive from mesenchymal cells [2] and count more than 50 different histological subtypes. Surgical excision is the cornerstone of localised STSs treatment, and margins status is one of the most important factors affecting recurrence-free survival [3] .
Radiotherapy (RT) is part of the multimodality treatment of soft tissue sarcoma; in particular, adjuvant radiotherapy after conservative surgery guarantees a local control comparable to radical surgery [4] .
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The role of chemotherapy in localised STSs patients following curative surgery is debated; two large meta-analyses evaluating the role of adjuvant chemotherapy in STSs found a small but significant reduction in the incidence of local and distant recurrences and an improvement of survival in patients treated with anthracycline-based post-operative chemotherapy [5, 6] . However, the reported high rate of skin toxicity correlated with the association of radiotherapy and anthracycline-based chemotherapy [7] , and very few retrospective studies reporting the safety of concomitant treatment in soft tissue sarcoma result in an uncommon use of concurrent radio-chemotherapy in STS patients. For these reasons, the use of concurrent adjuvant radio-chemotherapy is infrequent in STS patients.
The aim of our study is to compare clinical outcome and toxicity of two cohorts of patients matched for clinical and pathological characteristics treated with the association of radiotherapy and chemotherapy or radiotherapy alone for localised soft tissue sarcoma following upfront surgery.
Materials and methods
We retrospectively reviewed data from patients treated at our institution for soft tissue sarcoma between 1994 and 2014. Patients were eligible for this study in the presence of the following inclusion criteria: (1) histologically confirmed soft tissue sarcoma treated with upfront surgery (2) curative resection with negative margins (3) no evidence of distant metastases at the time of surgery (4) receiving post-operatively at least 60 Gy in 2 Gy fractions as adjuvant treatment with or without concurrent chemotherapy (5) in patients treated with chemotherapy, administration of at least three cycles of an anthracycline-based regimen, of whom at least one during the radiotherapy course. Patients with histological diagnosis of Ewing's sarcoma, Rhabdomyosarcoma, Desmoid tumours, Dermatofibrosarcoma Protuberans, extraskeletal osteosarcoma and previously irradiated patients were excluded from this study. A matched-pair analysis was performed to compare rates of local control (LC), distant metastases-free survival rates (DMFS), overall survival (OS) and treatment-related toxicities between patients receiving adjuvant radiotherapy (RT) and chemoradiotherapy (CRT) following surgical excision of the primary tumour.
For each patient in the CRT group, a corresponding pair in RT group was identified by matching for age (superior or inferior/equal to 65 years), grading according to FNCLCC [8] and T stage according to TNM classification system for sarcoma [9] . In the event that a matched pair was not appropriately identified, case was not retained for subsequent analysis. Conversely, whenever multiple matches were possible, the patient whose treatment date was the closest to its counterpart in the other group was selected. Data were manually cross-checked with random-sampling verification of the matching process.
Radiotherapy
Tumour bed was defined on the post-operative MRI taking into account the extension of the preoperative gross volume, an expansion of 1.5 cm radially and 4 cm longitudinally was done to obtain the clinical target volume (CTV) and the planning target volume (PTV) was derived from the CTV + 0.5 cm in all directions. Using a 3D conformal radiotherapy technique in most cases two lateral tangential fields were used to irradiate the post-operative volume. Radiation energies of 6 MV and 10 MV were used. After 2011, patients were treated with helical tomotherapy. The prescribed dose was 60-66 Gy with a standard fractionation of 2 Gy daily. Radiotherapy toxicity was assessed by the RTOG/EORTC criteria; local early toxicity was clinically rated once a week during irradiation. Late toxicity was recorded during followup that was performed every 3 months for the first 2 years, every 6 months for 3 years and annually thereafter.
Chemotherapy
Chemotherapy was considered associated to radiotherapy if patients received at least one cycle of chemotherapy concurrently to radiotherapy course. Chemotherapy consisted of three or five cycles of epirubicine (60 mg/m 2 Day 1-2) and ifosfamide (3 g/m 2 Day 1-3) administered every 21 days. Five cycles of adjuvant chemotherapy were the therapeutic standard before 2012, thereafter three cycles were administered when the Italian sarcoma group and the Spanish sarcoma group published a randomised clinical study demonstrating that three cycles of preoperative chemotherapy were not inferior to three preoperative cycles followed by two post-operative cycles of chemotherapy [10] .
Granulocyte colony-stimulating factor was administered day 4. The toxicities were recorded according to the Common Terminology Criteria for Adverse Events (CTCAE) v 4.0. [11] .
Statistical analysis
Overall survival (OS) was calculated from the date of surgery to the time of the last follow-up or death, and local relapse-free survival (LRFS) and distant relapse-free survival (DMFS) were calculated from the surgery to the time of the local recurrence and the time of the distant metastasis development, respectively. For each endpoint, survival plots were elaborated using the Kaplan-Meier method: the statistical significance of differences among survival curves was analysed using the log-rank test. Toxicity rates were compared using the Chi-square test. A p value inferior to 0.05
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was considered statistically significant. Statistical analysis was performed using the SEM software (SILEX Development, Mirefleurs, France).
Results

Patients and treatment-related characteristics
One hundred and fifty-eight patients met the inclusion criteria. Among them, 90 patients were matched for age, grade and T (Table 1 ). There were 23 (51.1%) females in RT group and 24 (53.3%) females in the concomitant treatment group. Median age in radio-chemotherapy group was 48.8 years (range 18-71) and 49.5 years (range 16-75) in patients receiving radiotherapy alone. The most representative histologies were: liposarcoma (23.3%), myxofibrosarcoma (18.9%), leiomyosarcoma (15.6%) and undifferentiated pleomorphic sarcoma (11.1%). Seventy (77.8) patients had a tumour larger than 5 cm. Seventy-three (81.1) patients underwent wide surgical excision. Post-operative radiotherapy was delivered with 3D conformal technique in 76 (84.4%) patients, and 14 (15.6%) underwent helical tomotherapy. The radiotherapy dose ranged between 60 and 66 Gy, and 50 (55.6%) patients received more than 60 Gy. No significant differences in terms of gender, margin status and radiotherapy dose were found between the two groups.
Among patients who received chemotherapy, 24 (53.3%) received 5 cycles, while in 21 (46.7%) patients, three cycles were administered. The chemoradiotherapy group associated one or two cycles of chemotherapy to radiotherapy; 38 (84.4%) patients received two cycles of chemotherapy concurrently to radiotherapy.
Outcome
The median follow-up was 61 months (range: 4-257) in the radiotherapy group and 58 months (range: 7-217) in the concurrent radio-chemotherapy group. Nineteen (21.1%) patients developed local recurrence, 13 (28.9%) in the radiotherapy group and 6 (13.6%) in RTCT group. Overall 5-year local relapse-free survival was 83% (Fig. 1 ). There were no differences in terms of local recurrence rate between the radio-chemotherapy group and radiotherapy alone group (Fig. 2) .
At the univariate analysis, factors correlated to a higher rate of local relapse were stage T2 (p = 0.01) and age older than 65 years (p = 0.01). None of the variables analysed was found as independent prognostic factor of local relapse at multivariate analysis.
A total of 29 patients developed distant metastases, in particular 14 (15.6%) patients in the RTCT group and 15 (16.7%) patients in the RT group. The 5-year distant metastases-free survival was 67% (Fig. 3 ). There were no differences in terms of distant recurrence rate between the radio-chemotherapy group and radiotherapy alone group (Fig. 4) . The most common sites of distant metastases were lungs and bones. In both treatments, group 9 (10%) and 2 (2.2%) patients developed lung and bone metastases, respectively. Four (8.9%) patients in RT group and 3 (6.7%) in the RTCT group developed both lung and bone metastases.
At the univariate analysis, patients with an ECOG performance status (PS) = 1 had a higher rate of distant relapse than patients with PS = 0 (p = 0.034). Stage T2 (p = 0.022) and age older than 65 years (p = 0.0001) were associated to distant relapse. Multivariate analysis revealed an association between age > 65 years and distant metastases (Hazard Ratio (HR) = 5.7, 95% CI 2.7-11.9; p = 0.001).
At the time of analysis, 15(16.7%) patients were dead, 6 (6.7%) patients in the RTCT group and 9 (10%) patients in the RT group. The 5-year overall survival was 88% (Fig. 5 ).
Five year overall survival was 82% and 96% in RT alone and RTCT group, respectively. At statistical analysis there was no difference in 5-year survival between the two groups (Fig. 6 ). Fourteen patients (15.6%) had tumour-related deaths, one (1.1%) patient in the RTCT group was dead due to other causes. In the RTCT group, among tumourrelated deaths, there were 3 (6.7%) metastatic patients and 2 (4.4%) patients with both local and distant relapse; in the RT group 2 (4.4%) patients had metastatic disease and 7 (15.6%) patients suffered from both local and distant recurrence. Univariate analysis revealed a correlation between age older than 65 years and death (p = 0.025). At multivariate analysis, age > 65 years was an independent prognostic factor of overall survival (HR 3.7, 95% CI 1.2-12.1, p = 0.037).
Toxicity
Acute radiotherapy toxicity was recorded during radiotherapy course, and 15 (16.7%) patients developed grade 2 radiation dermatitis; of these, 6 (6.7%) patients received associated chemotherapy. Grade 3 dermatitis was recorded in 15 (16.7%) patients; of these, 6 (6.7%) patients received chemotherapy; local toxicity was developed at a median dose of 56.6 Gy (range: 38-66). At a dose of 35 Gy, a patient, who received radiotherapy alone, had a wound complication that needed a minor surgical approach. Comparison between two treatment groups did not reveal differences in frequencies of skin toxicity. During follow-up, 12 (13.3%) patients developed grade 2 late fibrosis, 3 (3.3%) joint stiffness and 1 (1.1%) patient experienced a bone fracture 1 year after the end of radiotherapy treatment.
Haematological toxicity was recorded only in patients treated with chemotherapy: anaemia, thrombocytopenia and neutropenia resulted significantly higher in the RTCT group than in patients treated with radiotherapy alone (p < 0.001, p = 0.002 and p = 0.008, respectively). Six (13.3%) patients interrupted chemotherapy due to haematological toxicity: in particular, 2 (4.4%) patients experienced grade 4 neutropenia, 3(6.7%) patients had grade 3 anaemia and 1 (2.2%) patient developed grade 3 thrombocytopenia.
Discussion
Soft tissue sarcomas are a rare group of tumours treated with a multidisciplinary approach. In locally advanced soft tissue sarcoma, surgery is the cornerstone of treatment and radiotherapy in preoperative or post-operative setting is complementary to conservative surgery to guarantee a local control comparable to radical surgery [12] .
The role of adjuvant chemotherapy in localised soft tissue sarcoma is still controversial [13] . For this reason, the interest of this study was focused to investigate differences in clinical outcome of patients treated with concurrent radio-and chemotherapy compared to patients treated with radiotherapy alone for localised soft tissue sarcoma. Although our study has some limits such as the retrospective nature, the limited number of patients and the impossibility to analyse the differences between the histological subgroups due to the small population size, it provides a balanced evaluation of the impact of the chemotherapy in adjunction to radiotherapy on the outcome of localised soft tissue sarcoma patients. In particular, a matched cohort analysis was used, using the most important prognostic factors affecting local and distant control and survival. Patients with comparable tumour stage, grade and age were divided into two groups depending on the treatment received. The study failed to show any benefit in terms of local and distant control and survival between the two groups.
In a recent trial, Nesseler et al. [7] published a retrospective cohort study analysing 51 patients treated with radiotherapy and 29 patients with radio-chemotherapy for soft tissue sarcoma. At a median follow-up of 68 months (range: 9-284), the authors found no differences in terms of disease-free survival (HR 1.096, 95% CI 0.519-2.315), distant metastasis-free survival (HR 1.469, 95% CI 0.668-3.228) and overall survival (HR 1.378, 95% CI 0.498-3.814) between patients treated with chemoradiotherapy or radiotherapy alone. This study is one of the latest that reported the outcome of adjuvant chemoradiotherapy in STSs, but before other studies investigated the role of post-operative chemotherapy in the same setting. A recent pooled analysis of two EORTC phase III trials [14] comparing adjuvant anthracycline-based chemotherapy to a control in localised soft tissue patients enrolled a total of 819 patients with a median follow-up of 8.2 years. A benefit of adjuvant chemotherapy in terms of relapse-free survival was correlated to factors such as male gender and patients age older than 40. A worse local control and overall survival was found in patients with positive surgical margins (R1). The authors concluded that chemotherapy is an investigational procedure, and it is not recommended routinely in localised STSs. In a large database, analysis included 3422 patients diagnosed with localised high-grade and large tumour (> 8 cm) [15] ; the clinical choice to prescribe chemotherapy and/or radiotherapy in the perioperative setting and the clinical benefit of these treatments were investigated. A total of 1839 patients received a single treatment modality (chemotherapy or radiotherapy); chemoradiotherapy was administered in the 21% (714) of patients. At a median follow-up of 49 months (28-72 months), the 5-year overall survival was 62.1% in patients treated with radio-chemotherapy compared to 35.7% with surgery alone and 49.4% with radiotherapy or chemotherapy in the perioperative setting (p < 0.001); mortality HR was reduced by 37% with radiotherapy and by 24% with chemotherapy. The improvement of 5-year survival in patients treated with chemotherapy (12%, from 45 to 57%; p < 0.001) was comparable to the benefit obtained in a metaanalysis in which the combination of doxorubicin and ifosfamide conferred a better survival in chemotherapy group (OR 0.56, 95% CI 0.36-0.85, p = 0.01) compared to surgery alone [6] . Nowadays, chemotherapy resulted in improved local and distant control in large studies not confirmed in smaller series. In most cases, randomised studies and retrospective series such as the present study that did not find a significant impact of chemotherapy in perioperative treatment of soft tissue sarcoma analysed a limited number of patients, and it could result in a not sufficient population size to be powered to observe survival difference. Moreover, soft tissue sarcoma is a heterogeneous disease including more than 50 different histological subtypes with different prognosis and sensibility to chemotherapy; the absence of subgroup analysis for histological subtypes could not individualise patients with unfavourable histology that could benefit from chemotherapy. Future studies with larger population stratified according to histology are necessary to identify high-risk patients who could benefit from chemotherapy.
Moreover, the caution to administered chemotherapy concurrent to radiotherapy is due to the well-known increased risk of toxicity; historically, in breast cancer patients, the concurrent administration of anthracyclines with radiotherapy was correlated to high risk of radiation dermatitis and cardiac toxicity; for this reason, a sequential treatment is preferred [16] . Nesseler et al. [7] analysing the acute toxicity correlated to the concurrent radio-chemotherapy treatment for high-grade sarcoma recorded grade 3 dermatitis in the 48.3% of patients that was significantly higher compared to patients treated with radiotherapy alone (OR 6.99 95% CI 2.28-21.47, p < 0.01). The late toxicity in RTCT group was four folds higher than in RT alone group (20.7% and 5.9%, respectively), but the difference was not statistically significant (p = 0.06). If on the one hand, the early skin toxicity was well managed with supportive care, the authors correlated the higher late toxicity possibly to the 3D conformal radiotherapy technique that could not spare the dose to the organs at risk. In our matched analysis, the concurrent radiotherapy treatment was well tolerated and only 6 (22.2%) patients in the RTCT group experienced grade 3 radiation dermatitis. Regarding the late toxicity, 6 (22.2%) patients developed grade 2 fibrosis. The only bone fracture developed at 1 year of follow-up occurred in a patient treated with radiotherapy alone; in this case, a large volume of the femur was included in the treatment volume due to the bone involvement. No difference in toxicity was found between the two treatment groups.
The acceptable toxicity profile of concurrent radiochemotherapy in this study could be explained first of all because in the 15.6% of patients, radiotherapy was delivered with helical tomotherapy, a high conformal technique that reduced the dose to the organs at risk [17] . Furthermore, with respect to other study that considers tumour size ≥ 8 cm, in our study, the 22.2% of patients had a tumour smaller or equal to 5 cm resulting in smaller treatment volume that correlates with a lower risk of local toxicity [18] . Finally, to reduce the risk of radiation dermatitis, during the radiotherapy, contouring the treatment volume usually had a 3 mm gap from patient surface to decrease the dose to the skin. [19] .
If on the one hand chemotherapy did not affect clinical outcome, age was an important prognostic factor in the population studied. According to most series, this study found worse prognosis in elderly patients. At the last follow-up, 29 (32.2%) patients developed distant metastases and 15 (16.7%) patients were dead. Age older than 65 years was an independent prognostic factor of distant relapse-free survival (HR 5.7, 95% CI 2.7-11.9; p = 0.001) and overall survival (HR 3.7, 95% CI 1.2-12.1, p = 0.037). It is accepted that the incidence of cancer increases with age due to the summation of genetic and epigenetic mutations during the life that favours the carcinogenesis [20] . Moreover, elderly patients often had larger tumours due to late diagnosis and highergrade tumours probably associated to the higher incidence of genetic aberrations in elderly patients [21] . Furthermore, elderly patients usually receive suboptimal treatment with respect to local or systemic control of disease compared to younger patients. Surgery is the most important approach in STSs, but in elderly population, the decreased performance status and comorbidities that could be associated with postoperative complications sometimes excluded this treatment. Tsuda et al. [22] analysed 202 soft tissue sarcoma patients aged ≥ 65 who underwent surgery. Geriatric assessment, Charlson comorbidity index, high-sensitivity-modified Glasgow prognostic score (Hs-mGPS) and clinical and tumour characteristics were collected. The 5-year specific sarcoma survival was 79%, and 5-year event-free survival was 71.3%. Specific sarcoma survival correlated with stage [hazard ratio (HR) for III vs. II-I, 2.81; 95% CI, 1.30-6.06; p = 0.009], surgical margin (HR for R1 vs. R0, 3.17; 95% CI, 1.63-6.17; p = 0.001) and performance status (HR for 2 vs. 0 or 1, 2.15; 95% CI, 1.04-4.44; p = 0.038). Event-free survival was significantly correlated with surgical margin (HR for R1 vs. R0, 2.56; 95% CI, 1.53-4.29; p < 0.001), Hs-mGPS (HR for ≥ 1 vs. 0, 1.74; 95% CI, 1.01-2.99; p = 0.046) and performance status (HR for 2 vs. 0 or 1, 1.95; 95% CI, 1.05-3.60; p = 0.034). 16.8% of patients experienced post-operative complications. The authors concluded that elderly patients must be treated with a surgical approach such as the younger patients but that it is necessary to select elderly patients according to specific geriatric scale to guarantee the better approach to this vulnerable population. Furthermore, the use of perioperative chemotherapy and/or radiotherapy declines with age. In particular, anthracycline-based chemotherapy increases the incidence of chemotherapy-related toxicity in 1 3 elderly patients [23] , and the investigational use of novel agents with a better toxicity profile could be difficult considering the low presence of elderly patients in clinical targets. The uncommon use of radiotherapy in this population is often correlated to logistical difficulties and patient refusal.
In conclusion, this study did not demonstrate an increase in clinical outcome correlated with the administration of adjuvant chemotherapy in high-risk soft tissue sarcoma patients. Larger studies and subgroup analysis according to histology are necessaries to confer a definitive role of chemotherapy in STSs. Older age is a poor prognostic factor in STS patients, and a tailored approach for elderly patients is necessary to guarantee an increase in clinical outcome in this unfavourable population.
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